EV-302 Patient-Reported Outcomes

Panel Comments on Ongoing EV-302 Trial, Patient Management Considerations in Bladder CancerПодробнее

Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles, MDПодробнее

Integrating patient-reported outcomes into cancer clinical trialsПодробнее

Patient-Reported Outcomes for Toxicity and Symptom Monitoring in OncologyПодробнее

Segment 6 - Patient-Reported Outcomes and Other Important MeasuresПодробнее

Understanding Electronic Patient-Reported Outcomes (ePRO) in Clinical TrialsПодробнее

Panel Shares Thoughts on EV-302 Study: Response Rate, Toxicities, Progression, and MoreПодробнее

EV-302: advancing treatment for metastatic urothelial carcinomaПодробнее

EV-302 Results and How They Compare to the JAVELIN ParadigmПодробнее

EV 302 KEYNOTE A39 I Congresso Europeu de Oncologia - ESMO 2023Подробнее

Positive Correlation in Patient-Reported Outcomes in Phase III ENLIVEN TrialПодробнее

Impact of telemedicine on patient-reported outcomes in urologic oncologyПодробнее

Positive Correlation With Patient-Reported Outcomes Seen in Phase III ENLIVEN TrialПодробнее

8-Dec-2020 Summit: Patient-Reported Outcome Measures, Patients Redefining Health Care in CanadaПодробнее

Impact of Patient Reported Outcomes on Patient CareПодробнее

Patient-reported outcomes in HSCTПодробнее

Patient-reported Outcomes with TKIs: Quality of Life and Side EffectsПодробнее

Patient-Reported Outcome Measures After Aseptic Revision TKAПодробнее

PANEL - Patient reported outcomes measures consultations perspectives from clinicians and patientsПодробнее